CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations·REDWOOD CITY, CA·FY end 12/31·CIK 1088856

CEO Pay Ratio

46:1

CEO Total Comp

—

Median Employee

$334,040

Revenue

$761.4M

FY 2025

Net Income

$99.7M

FY 2025

Free Cash Flow

$141.8M

FY 2025

Net Margin

13.1%

Insider Net (180d)

-$2.6M

2 buys / 6 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$761.4M	$675.0M	$482.4M	$401.9M	$366.0M
Gross Profit	—	—	—	—	—	—
Operating Income	$44.8M	$137.0M	$107.3M	$112.6M	$124.5M
Net Income	$99.7M	$141.2M	$106.1M	$101.4M	$112.5M
Operating CF	$142.0M	$198.1M	$127.0M	$120.3M	$167.9M
Capex	$211.0K	$2.2M	$139.0K	$413.0K	$469.0K
Free Cash Flow	$141.8M	$195.9M	$126.9M	$119.9M	$167.4M
Buybacks	$172.9M	$15.7M	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	5.9%	20.3%	22.2%	28.0%	34.0%
Net Margin	13.1%	20.9%	22.0%	25.2%	30.7%
FCF Margin	18.6%	29.0%	26.3%	29.8%	45.7%
R&D / Revenue	33.5%	36.6%	38.2%	32.6%	31.1%
Effective Tax	-49.9%	12.6%	14.8%	12.7%	10.0%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	122.0%	8.0%	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Joseph K. BelanoffM.D.	$1.2M	—	$12.9M	$1.2M	$23.5K	$15.3M
Charles RobbChief Business Officer and	$711.4K	$124.5K	$5.2M	$358.0K	$23.5K	$6.4M
William GuyerPharm.D.	$706.4K	$17.9K	$5.2M	$429.6K	$23.5K	$6.3M
Sean MaduckPresident	$648.9K	$112.0K	$5.2M	$261.2K	$23.5K	$6.2M
Atabak MokariChief Financial Officer and	$566.3K	$97.7K	$5.2M	$285.0K	$23.5K	$6.1M
Corcept Endocrinology	$601.6K	$97.3K	$2.8M	$422.8K	$22.5K	$3.9M